For the past 19 years, Dr. Vera has worked extensively on developing novel T cell therapies for clinical applications and has an extensive expertise in performing research in the field of adoptive T cell therapy. Dr. Vera has made several contributions in the field, specifically in the areas of developing and streamlining therapeutic candidates from the research bench to the clinic and from academia to industry.
Dr. Vera is a co-founder of Marker Therapeutics and AlloVir, and he has previously collaborated with Celgene and Bluebird Bio in developing novel CAR T cell therapies.
Prior to his appointment as CEO, Dr. Vera served as the Chief Operating Officer and Chief Scientific Officer of Marker Therapeutics. Before joining Marker, Dr. Vera was Associate Professor in the Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston. He is a co-investigator on several clinical trials for T cell therapy in both infectious disease and cancer. Dr. Vera has published more than 30 articles and is a named inventor on 13 published patents.
In recognition of his work, Dr. Vera has received several prestigious awards including the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. Dr. Vera attained his M.D. from the University El Bosque in Bogota, Colombia.
Monic Stuart is an experienced hematologist with over 20 years in clinical drug development. Most recently, Dr. Stuart served as interim Chief Medical Officer, Head of Clinical Development or Clinical Advisor for numerous biotechnology and pharmaceutical companies worldwide, where she has developed clinical strategy including clinical development plans, Phase 1-3 study designs and protocol development for a variety of benign and malignant hematologic, solid tumor, and supportive care indications. In this capacity, she has helped to successfully execute an NDA, multiple INDs and breakthrough designation packages. Dr. Stuart previously served as Vice President of Clinical Development at Geron Corporation, where she spearheaded efforts to develop a telomerase inhibitor in myeloid malignancies. Before her role at Geron Corp., she worked at Genentech Inc. as a Senior Medical Director in the Oncology Division. During her time at Genentech, she served in leadership position for multiple early and late stage hematology/oncology programs. Prior to joining Genentech, Dr. Stuart served as an attending physician in the Division of Blood and Marrow Transplantation at Stanford University, where she led trials in myeloid malignancies. Dr Stuart received her M.D and B.S. in Biology from the University of North Carolina at Chapel Hill. She completed her medical residency in internal medicine and fellowships in hematology and bone marrow transplantation at Stanford University. Dr. Stuart also holds a Master’s Degree from the School of Public Health at Johns Hopkins University.
Nadia Agopyan joined Marker in August 2019 from Kite Pharma, a subsidiary of Gilead Sciences, where she served as Director of Regulatory Affairs, Global Regulatory Lead. In this role, she was responsible for overseeing the global marketing authorization and lifecycle management of the YESCARTA® franchise, defining the global regulatory strategies for CAR T cell products in lymphoma/leukemia, and overseeing clinical programs from Phase 1-4 development, in addition to operational aspects of global regulatory submissions. Previously, she served as Global Regulatory Lead at Baxter Biosciences leading Vonvendi (recombinant von Willebrand Factor) approval/launch, Senior Director Regulatory Affairs at Ambit Biosciences, and Director Regulatory Affairs at Cougar Biotechnology, a unit of Johnson and Johnson Ortho Biotech Oncology, where she led the approval of Zytiga, abiraterone acetate, for the treatment of patients with metastatic castrate-resistant prostate cancer. Earlier in her career, Dr. Agopyan served in various roles at biotechnology companies such as Amgen, CATO Research and Allelix Biopharmaceuticals and as Assistant Professor in academia including Duke University and University of Toronto. She earned her Ph.D. and B.Sc. in Neurophysiology from McGill University (Montreal Canada).
Oumar is an accomplished leader with deep experience in cell and gene therapy manufacturing and technology, process development, qualification of cGMP production facilities and translational research laboratories. For the past 15 years, he has played a key role in building GMP manufacturing and quality organizations. Prior to joining Marker Therapeutics, he served as Director of Manufacturing and Process Development at Cell Medica. In this role he was leading the development of cell therapy products for phase II clinical trials. Prior to his time at Cell Medica, Oumar was Laboratory Manager of Cell and Gene Therapy at Baylor College of Medicine coordinating manufacturing activities for multiple phase I clinical trials. Oumar received his BS of Biotechnology and MBA at the University of Houston Downtown. Oumar lives in Houston, with his wife and 2 children. Oumar enjoys riding his bike, camping and family outdoor events.
Gerald Garrett brings over 29 years of clinical development experience in the Biopharmaceutical industry to the team. Prior to joining Marker Therapeutics, Inc., he owned and operated a small Contract Research Organization focused on providing clinical and project management leadership to multi-functional project teams in a variety of therapeutic areas with a focus on Phase 1-2 oncology clinical trials. Mr. Garrett spent his early as a study coordinator, a CRA for Fujisawa and Burroughs Wellcome and led the development of the Project Management team at Clinimetrics, Inc.
Tsvetelina P. Hoang brings over 15 years of experience in cancer immunotherapy, including antibody-based and adoptive cell therapies. Most recently, she was the Director of Translational Research at Bellicum Pharmaceuticals where she oversaw the pre-clinical development of the company’s T cell receptor (TCR) and chimeric antigen receptor (CAR)-engineered T cell therapy programs and the translation of those programs into the clinic. Previously, she was a member of the faculty at The University of Texas MD Anderson Cancer Center, investigating the molecular mechanisms of immune checkpoint inhibitors’ function. Dr. Hoang worked closely with Dr. James Allison, the 2018 Nobel Laureate in medicine and a renowned pioneer in the field of tumor immunotherapy, as a member of his team at University of California-Berkeley, Memorial Sloan-Kettering Cancer Center and MD Anderson Cancer Center. She earned her Ph.D. from Johns Hopkins University and holds a combined B.S./M.S. degree with distinction, magna cum laude, from Yale University. She was a recipient of a Cancer Research Institute fellowship and is a member of the Phi Beta Kappa honor society.
Edmund Cheung has more than twenty years of professional experience in the Human Resources field. Prior to joining Marker Therapeutics, Mr. Cheung served as Associate Vice President of Human Resources at Baylor Genetics where he was responsible for all aspects of the company’s HR strategies and functions. Previously, he held management and HR roles at Baker Hughes, a Global Fortune 500 energy technology and oil-field services company, and Houston Methodist Hospital, a leading Hospital group in Houston. Mr. Cheung earned his BA in Psychology at Baylor University, and an MBA from the University of Houston.